TY - JOUR T1 - Biomarkers for Predicting Complete Debulking in Ovarian Cancer: Lessons to Be Learned JF - Anticancer Research JO - Anticancer Res SP - 679 LP - 682 VL - 34 IS - 2 AU - CARSTEN LINDBERG FAGÖ-OLSEN AU - BENT OTTESEN AU - IB JARLE CHRISTENSEN AU - ESTRID HØGDALL AU - LENE LUNDVALL AU - LOTTE NEDERGAARD AU - SVEND-AAGE ENGELHOLM AU - SOFIE LEISBY ANTONSEN AU - MAGNUS LYDOLPH AU - CLAUS HØGDALL Y1 - 2014/02/01 UR - http://ar.iiarjournals.org/content/34/2/679.abstract N2 - Aim: We aimed to construct and validate a model based on biomarkers to predict complete primary debulking surgery for ovarian cancer patients. Patients and Methods: The study consisted of three parts: Part I: Biomarker data obtained from mass spectrometry, baseline data and, surgical outcome were used to construct predictive indices for complete tumour resection; Part II: sera from randomly selected patients from part I were analyzed using enzyme-linked immunosorbent assay (ELISA) to investigate the correlation to mass spectrometry; Part III: the indices from part I were validated in a new cohort of patients. Results: Part I: The area under the receiver operating characteristic curve (AUC) was 0.82 for both indices. Part II: Linear regression analysis gave an R2 value of 0.52 and 0.63 for transferrin and β2-microglobulin, respectively. Part III: The AUC of the two indices decreased to 0.64. Conclusion: Our validated model based on biomarkers was unable to predict surgical outcome for patients with ovarian cancer. ER -